Project Grant R21EY035812
- Federal Grant Award Summary Baylor College of Medicine received a $1.6M Project Grant from the National Eye Institute under the Vision Research program (CFDA 93.867) awarded on September 30, 2025, with completion targeted for September 29, 2028. The grant funds research investigating the Hippo and Wnt signaling pathway regulation of mammalian Muller glial cell (MG) reprogramming and proliferation. The primary deliverable is scientific research aimed at identifying cellular and molecular...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded The Johns Hopkins University a $695,018 Project Grant effective August 1, 2025, through July 31, 2030, to conduct research on the regulation of retinal ganglion cell regeneration through Müller glia (MG) cell function. The award supports a five-year investigation into how MG cells function as injury-responsive stem cells to enable retinal regeneration, with the ultimate goal...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a Project Grant of $255,340 to The Regents of the University of California, San Francisco for research on the development and regeneration of retinal ganglion cells in the vertebrate retina. The award, granted on May 1, 2026, with a completion date of April 30, 2031, supports fundamental research aimed at understanding gene regulatory networks that direct retinal ganglion cell differentiation during development and at...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $440,275 Project Grant to The Research Foundation for the State University of New York (RF SUNY) for research on ATOH7 interacting proteins involved in retinal ganglion cell (RGC) genesis. The two-year project, effective April 1, 2026 through March 31, 2028, is conducted under the Vision Research federal grant program (CFDA 93.867) and focuses on identifying and characterizing the protein factors that interact with ATOH7, a...
- Summary The National Eye Institute awarded a $1.01M Vision Research grant (CFDA 93.867) to Washington University in St. Louis beginning July 1, 2025, through March 31, 2030. The project, titled "Visual Feature Competition Between Central and Peripheral Retinal Pathways," will deliver fundamental neuroscience research investigating how the retina processes competing visual signals that control eye fixation and the optokinetic reflex (OKR). The primary products include empirical findings...
- This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $679,159 to The Schepens Eye Research Institute, Inc. to support research on "In Vivo Epigenetic Reprogramming of Retinal Ganglion Cells in Aging Mice with Glaucoma". The goal is to investigate how aging increases retinal ganglion cell susceptibility to stress and visual function loss in glaucoma, and to explore the potential of epigenetic reprogramming to reverse this age-related...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded Massachusetts Eye and Ear Infirmary a Project Grant of $663,406 (Award Date: April 1, 2026; Completion Date: March 31, 2031) under the Vision Research program (CFDA 93.867) to develop novel therapeutic interventions for retinitis pigmentosa (RP). The project will deliver research products including the development of an adeno-associated virus (AAV)-based retinoic acid signaling activator and empirical findings from...
- Federal Project Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded $902,000 to The Regents of the University of California, San Francisco for a two-year project (September 1, 2025–August 31, 2027) focused on multimodal characterization of a novel inherited mouse model of glaucoma. The research addresses the critical clinical need for neuroprotective therapeutic strategies for primary open-angle glaucoma (POAG), which affects over 80...
- Cooperative Agreement Summary The University of Rochester received a $744,451 Cooperative Agreement from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded on March 17, 2026, with an ultimate completion date of February 28, 2027. This agreement funds the development of proteolysis-targeting chimeras (PROTACs)—small molecule compounds designed to inhibit secretory phospholipase A2-IIA (sPLA2-IIA)—as a novel therapeutic approach for age-related macular...
- Federal Grant Award Summary This National Eye Institute (NEI) Vision Research program (CFDA 93.867) Project Grant award of $574,158 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University supports a five-year research initiative (September 1, 2025 through April 30, 2030) investigating the role of melanopsin in photoreceptor outer segment renewal. The research will produce empirical findings and mechanistic insights into how melanopsin, a photosensitive protein expressed...
CHARACTERIZATION OF THE NASCENT RETINAL PROTEOME REGULATING HIPPO SIGNALING DURING DAMAGE - PROJECT SUMMARY/ABSTRACT RETINAL DEGENERATIVE DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION AND GLAUCOMA, AS WELL AS TRAUMATIC INJURY, TYPICALLY LEAD TO LOSS OF RETINAL NEURONS AND THUS SIGHT. THEREFORE, THERE IS A CRITICAL NEED TO DEVELOP THERAPIES TO REGENERATE LOST RETINAL NEURONS FOR VISION RESTORATION. THE ABILITY FOR THIS TYPE OF INTRINSIC SELF-REPAIR NATURALLY OCCURS IN THE ZEBRAFISH RETINA. HERE, IN RESPONSE TO RETINAL DAMAGE, THE MULLER GLIAL CELLS (MGS) REPROGRAM TO A PROLIFERATIVE, PROGENITOR STATE CAPABLE OF GIVING RISE TO NEW RETINAL NEURONS THAT INTEGRATE INTO THE PRE-EXISTING RETINAL CIRCUITRY AND RESTORE VISION. WHILE MAMMALIAN MGS DO NOT EXHIBIT THE REGENERATIVE POTENTIAL OF THE ZEBRAFISH, THEY HAVE SIMILAR GENE EXPRESSION AND HOMEOSTATIC ROLES. ADDITIONALLY, IN RESPONSE TO DAMAGE, MOUSE MGS DISPLAY VERY LIMITED AND TRANSIENT ENTRY INTO THE CELL CYCLE. THESE DATA SUGGEST THAT AN INTRINSIC PROLIFERATIVE AND/OR REGENERATIVE BLOCK LIKELY PREVENTS MAMMALIAN MGS FROM UNDERGOING SUSTAINED CELL CYCLE RE-ENTRY AND ACQUIRING A MULTIPOTENTIAL PROGENITOR- LIKE STATE. RECENTLY, IT WAS SHOWN THAT THE HIPPO SIGNALING PATHWAY FUNCTIONS TO REPRESS SUSTAINED ACTIVITY OF THE TEAD TRANSCRIPTION COFACTOR YAP, WHICH IS REQUIRED FOR MG PROLIFERATION AND REPROGRAMMING. BY MANIPULATING THE HIPPO PATHWAY, MAMMALIAN MGS MIGHT BE ABLE TO ELICIT A ROBUST REGENERATIVE RESPONSE ANALOGOUS TO THE ZEBRAFISH. HOWEVER, THE UPSTREAM COMPONENTS THAT TRIGGER INITIAL YAP ACTIVATION IN MGS AND SUBSEQUENT REPRESSION BY HIPPO ARE STILL COMPLETELY UNKNOWN THEREBY LIMITING MOLECULAR ENTRY POINTS FOR THERAPEUTIC INTERVENTION. TO COMPLICATE MATTERS, THE HIPPO PATHWAY RESPONDS TO A WIDE VARIETY OF CONTEXT-DEPENDENT BIOCHEMICAL AND BIOPHYSICAL INPUTS. TO MOVE THE FIELD FORWARD WITH AN EYE TOWARD CLINICAL TRANSLATION, WE MUST IDENTIFY THE MG-SPECIFIC REGULATORS OF YAP AND THE HIPPO PATHWAY. THEREFORE, THIS PROPOSAL AIMS TO USE CELL TYPE-SPECIFIC METABOLIC LABELING AND PURIFICATION OF PROTEINS FOLLOWED BY MASS SPECTROSCOPY ON DAMAGED MOUSE RETINAE. THIS APPROACH, WHICH HAS YET TO BE PERFORMED ON THE MAMMALIAN RETINA, WILL ALLOW US TO DECIPHER THE NASCENT PROTEOMES OF DAMAGED PHOTORECEPTORS AND GANGLION CELLS ALONG WITH THE IMMEDIATE MG RESPONSE DURING THE PERIOD OF YAP ACTIVATION AND SUBSEQUENT HIPPO SIGNALING. THIS INFORMATION WILL GENERATE NEW HYPOTHESES AND LAY THE FOUNDATION FOR FUTURE STUDIES AIMED AT BROADENING POTENTIAL THERAPEUTIC TARGETS FOR MODULATION OF THE HIPPO PATHWAY TO PROMOTE RETINAL REGENERATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.0k | 8/1/25 | ||
| Not listed | $240.0k | 7/26/24 |